Acasti Receives Full Data for Phase II TRIFECTA Trial

By: via Benzinga
Acasti Pharma Inc. ("Acasti" or the "Corporation") (Nasdaq: ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.